May Hill Capital LLC Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

May Hill Capital LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 79.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,753 shares of the company's stock after acquiring an additional 3,883 shares during the period. May Hill Capital LLC's holdings in Novo Nordisk A/S were worth $608,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Revolve Wealth Partners LLC raised its stake in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Novo Nordisk A/S by 10.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 225,914 shares of the company's stock valued at $19,433,000 after acquiring an additional 21,331 shares during the period. Victory Capital Management Inc. raised its stake in Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after acquiring an additional 23,223 shares during the period. Proficio Capital Partners LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at about $13,282,000. Finally, HM Payson & Co. raised its stake in Novo Nordisk A/S by 7.7% in the 4th quarter. HM Payson & Co. now owns 4,441 shares of the company's stock valued at $382,000 after acquiring an additional 316 shares during the period. 11.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the topic of several analyst reports. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $0.31 during mid-day trading on Tuesday, hitting $69.63. The stock had a trading volume of 9,838,730 shares, compared to its average volume of 7,271,482. The firm has a market capitalization of $310.90 billion, a P/E ratio of 20.60, a P/E/G ratio of 1.35 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The firm's 50 day moving average is $70.10 and its 200 day moving average is $75.41. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion for the quarter. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.